Clinical Trials & Indication
Clinical Development Stage
IND/CTA
Phase 1/2
Registration Directed
Engineered HSV backbone
+ GM-CSF + GALV-GP R-
RP1
IGNYTE*
+/- Opdivo
IND/CTA Phase 1/2 Potentially
Registrational
Melanoma
(inc anti-PD1 failed)
ph1/2 complete
NMSC
(inc anti-PD1 failed)
MSI-H cancers
NSCLC
(anti-PD1 failed)
CERPASS#
+ Libtayo
IND/CTA Phase 1/2 Potentially
Registrational
CSCC
ARTACUS
Mono
IND/CTA Phase 1/2 Potentially
Registrational
CSCC organ transplant
Engineered HSV backbone
+ GM-CSF + GALV-GP R- + anti-CTLA-4
RP2
RP2-001-18*
+/- Opdivo
IND/CTA Phase 1/2 Potentially
Registrational
Solid tumors
Engineered HSV backbone
+ GALV-GP R- + anti-CTLA-4 + 4-1BBL + CD40L
RP3
RP3-301
+/- anti-PD1
IND/CTA Phase 1/2 Potentially
Registrational
Solid tumors